Clumps of RNA-binding proteins have been discovered in the nucleus of nerve cells derived from people with Parkinson’s disease, according to a new study. Generated by a “self-propagating” cycle, these clumps were different and separate from those made from the protein alpha-synuclein, a well-known feature of Parkinson’s. A second…
News
Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinson’s disease, and improved cognition in those with mild dementia. That’s according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio,…
Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease — into nerve cells and help it spread across the brain, according to a study in mice. “Now that we know how Aplp1 and Lag3 interact, we have a new way…
BrainTale’s noninvasive imaging analysis software, BrainTale-care, may be able to distinguish Parkinson’s disease from atypical parkinsonism. That’s according to data from an advanced MRI technique, called diffusion tensor imaging, that measures the diffusion of water molecules in the brain’s white matter. White matter contains nerve fibers…
People with Parkinson’s disease who don’t always take Nourianz (istradefylline) as prescribed are more likely to have fewer prescriptions for other approved medications and to have anxiety, mood changes, or cognitive problems, a study finds. Understanding how well patients follow the instructions for taking Nourianz, such as how…
An imaging agent for positron emission tomography (PET) scans allowed researchers to visualize, for the first time, abnormal alpha-synuclein protein clumps in the brains of living patients with Parkinson’s disease, a study showed. By detecting a hallmark feature of Parkinson’s found in relatively lower abundance in the brain compared…
Scientists at the Imperial College London in England have been awarded nearly £100,000, or about $125,000, by Parkinson’s UK to identify new therapeutic targets for Parkinson’s disease. The grant was awarded to Michael Johnson, PhD, and his team, and will fund efforts to harness the power of computers…
Once-daily treatment with Gain Therapeutics‘ GT-02287 rescued motor function and cognitive performance in a mouse model of Parkinson’s disease associated with mutations in the GBA1 gene. “These data further confirm our conviction that GT-02287 can slow or stop progression of Parkinson’s disease and given the cognitive decline observed…
The risk of developing Parkinson’s disease is double in adults older than 50 with anxiety relative to those without it in a recent U.K. study. Other Parkinson’s-associated symptoms, such as sleep issues, constipation, and tremors, were also associated with an elevated Parkinson’s risk in people with anxiety. “By understanding…
Kannalife Sciences has been awarded a $1.49 million grant from The Michael J. Fox Foundation (MJFF) to support the development of KLS-13019, the company’s novel cannabidiol- or CBD-derived therapy targeting neuroinflammation and mitochondrial dysfunction in Parkinson’s disease. KLS-13019 has shown promising results in preclinical models of…
Recent Posts
- Late-onset depression may foreshadow Parkinson’s diagnosis
- Being mad at each other and mad at Parkinson’s disease, too
- Parkinson’s muscle firing patterns different for women than for men
- Breathing CO2 activates brain cleanup signals in new Parkinson’s study
- Guest Voice: DBS surgery transformed my life with early-onset Parkinson’s